{"preliminary_commentary":{"by_channel":{"x_thread":5,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"AALL1521","nct_id":"NCT02723994","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=aall1521-nct02723994. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"Ruxolitinib in combination with chemotherapy","type":"EXPERIMENTAL"}],"collaborators":["Children's Oncology Group"],"completion_date":{"date":"2026-03-03","type":"ACTUAL"},"conditions":["Leukemia"],"enrollment":{"count":171,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Ruxolitinib","otherNames":["INCB018424"],"type":"DRUG"},{"name":"Asparaginase Erwinia Chrysanthemi","otherNames":[],"type":"DRUG"},{"name":"Cyclophosphamide","otherNames":[],"type":"DRUG"},{"name":"Cytarabine","otherNames":[],"type":"DRUG"},{"name":"Dexamethasone","otherNames":[],"type":"DRUG"},{"name":"Doxorubicin","otherNames":[],"type":"DRUG"},{"name":"Leucovorin Calcium","otherNames":[],"type":"DRUG"},{"name":"Mercaptopurine","otherNames":[],"type":"DRUG"},{"name":"Methotrexate","otherNames":[],"type":"DRUG"},{"name":"Pegaspargase","otherNames":[],"type":"DRUG"},{"name":"Prednisone","otherNames":[],"type":"DRUG"},{"name":"Thioguanine","otherNames":[],"type":"DRUG"},{"name":"Vincristine Sulfate","otherNames":[],"type":"DRUG"}],"last_update":"2026-03-11","lead_sponsor":"Incyte Corporation","official_title":"A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2026-03-03","type":"ACTUAL"},"primary_outcomes":[{"measure":"Part 1: Safety/tolerability of ruxolitinib in combination with chemotherapy as measured by adverse events (AEs), vital signs, clinical laboratory tests, and echocardiograms","timeFrame":"Part 1: AEs assessed from screening through up to 30 days after the last dose of study drug, expected to be 26 months (females) or 38 months (males)"},{"measure":"Part 2: Efficacy of ruxolitinib in combination with chemotherapy as measured by Event-free survival, defined as the percentage of patients alive without relapse, progression, or death at 3 years from study Day 1","timeFrame":"Part 2: assessed at 3 years"}],"references":[],"start_date":{"date":"2016-09-30","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia","url":"https://clinicaltrials.gov/study/NCT02723994"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/aall1521-nct02723994"}